#Keynote 024 trial trial

Cooperative Oncology Research Group), Dublin, Ireland 11. The KEYNOTE-024 trial is generalisable to clinical practice in England. However, the utility of pembrolizumab in patients with metastatic NSCLC is dependent on PD-L1 expression, Raez explains. Jamess Hospital and Cancer Trials Ireland (formerly ICORG All Ireland. This is important because less than 5% of this patient population could be cured only 20 years ago, but the 5-year survival data from KEYNOTE-024 showthe number has drastically increased. Now, 5-year survival have emerged, demonstrating clinically meaningful long-term overall survival benefit with the checkpoint inhibitor compared with chemotherapy, Raez says. The KEYNOTE-024 trial evaluated pembrolizumab (Keytruda) vs platinum-based chemotherapy regimens in patients with metastatic NSCLC. In the phase III KEYNOTE-024 trial, 305 patients who had no prior treatment for metastatic NSCLC and tumor proportion score 50, those who received pembrolizumab (200 mg every 3 weeks) had a significant improvement in progression-free survival (hazard ratio HR 0.50 95 confidence interval CI 0.370.68 P <. Raez, MD, FACP, FCCP, hematology and oncology, Medical Director, Chief Scientific Officer, Memorial Cancer Institute, Memorial Healthcare System, discusses the clinical implications of the phase 3 KEYNOTE-024 trial (NCT02142738) in non–small cell lung cancer (NSCLC). The KEYNOTE-024 trial 17 established a role for the antiPD-1 antibody pembrolizumab versus chemotherapy as first-line treatment in patients with NSCLC with a PD-L1 expression level of 50 or.